Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
871 people get HSP articles and Market Currents by email alert.
Get email alerts on HSP »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
PR Newswire (May 14, 2013)
-
PR Newswire (May 8, 2013)
-
-
PR Newswire (May 1, 2013)
-
Business Wire (Apr 24, 2013)
-
PR Newswire (Apr 17, 2013)
-
PR Newswire (Apr 15, 2013)
-
CareFusion On The Right PathStephen Simpson • Wed, Apr 3 -
PR Newswire (Apr 2, 2013)
-
PR Newswire (Mar 18, 2013)
-
-
PR Newswire (Mar 1, 2013)
-
-
-
PR Newswire (Feb 13, 2013)
-
-
-
-
Hospira: Earnings PreviewZacks Investment Research • Tue, Jul 26, 2011 -
Hospira Earnings PreviewZacks Investment Research • Mon, Apr 25, 2011
-
Hospira's Earnings Hurt by Numerous FactorsZacks Investment Research • Tue, Apr 12, 2011
-
Hospira Receives Australian Approval for NivestimZacks Investment Research • Tue, Sep 28, 2010
-
Hospira Surges Ahead, Raises 2010 GuidanceZacks Investment Research • Wed, Apr 28, 2010
-
Hospira Is a Classic Successful Spin-Off StockJohn Clark • Sun, Mar 21, 2010 -
Hospira Ups 2009 GuidanceZacks Investment Research • Mon, Oct 5, 2009
-
-
CareFusion On The Right PathStephen Simpson • Wed, Apr 3
-
-
-
-
-
ICU Medical: Possible Takeover Target/Promising Small-Cap StockDavid Zanoni • Wed, Nov 7, 2012 -
-
Top Medtech Analyst Points To Post-Obamacare OpportunitiesLife Sciences Report • Thu, Sep 6, 2012 -
-
-
-
-
Baxter Still Defensive, But Is Now The Time For Offense?Stephen Simpson • Tue, May 15, 2012
-
-
Appeals Court Affirms Hospira Cancer Drug Win Over Sanofi-AventisDaniel B. Ravicher • Tue, Apr 10, 2012 -
-
-
-
-
Hospira Management Discusses Q2 2012 Results - Earnings Call TranscriptWed, Aug 1, 2012 • 1 Comment
-
Hospira's CEO Discusses Q1 2012 Results - Earnings Call TranscriptTue, May 1, 2012
-
Hospira Management Discusses Q4 2011 Results - Earnings Call TranscriptTue, Feb 14, 2012
-
Hospira's CEO Discusses Q3 2011 Results - Earnings Call TranscriptWed, Oct 26, 2011 • 2 Comments
-
Hospira Inc., 2011 Guidance/Update Call, Oct 18, 2011Tue, Oct 18, 2011
-
Hospira's CEO Discusses Q2 2011 Results - Earnings Call TranscriptWed, Jul 27, 2011
-
Hospira's CEO Discusses Q1 2011 Results - Earnings Call TranscriptTue, Apr 26, 2011
-
Hospira's CEO Discusses Q4 2010 Results - Earnings Call TranscriptWed, Feb 2, 2011
-
Hospira, Inc CEO Discusses Q3 2010 - Earnings Call TranscriptTue, Oct 26, 2010
-
Hospira, Inc. Q1 2010 Earnings Call TranscriptTue, Apr 27, 2010
-
Hospira Inc Q4 2009 Earnings Call TranscriptThu, Feb 4, 2010
-
Hospira, Inc. Q3 2009 Earnings Call TranscriptTue, Oct 27, 2009
-
Hospira Inc. Q2 2009 Earnings Call TranscriptWed, Jul 29, 2009
-
Hospira Q1 2009 Earnings Call TranscriptTue, Apr 28, 2009
-
Hospira, Inc. Q4 2008 Earnings Call TranscriptTue, Feb 17, 2009
-
Hospira Inc. Q3 2008 Earnings Call TranscriptWed, Nov 5, 2008
-
PR Newswire (May 14, 2013)
-
PR Newswire (May 8, 2013)
-
PR Newswire (May 1, 2013)
-
Business Wire (Apr 24, 2013)
-
PR Newswire (Apr 17, 2013)
-
PR Newswire (Apr 15, 2013)
-
PR Newswire (Apr 2, 2013)
-
PR Newswire (Mar 18, 2013)
-
PR Newswire (Mar 1, 2013)
-
at MarketWatch.com (Feb 14, 2013)
-
at MarketWatch.com (Feb 14, 2013)
-
at MarketWatch.com (Feb 13, 2013)
-
PR Newswire (Feb 13, 2013)
-
PR Newswire (Feb 5, 2013)
-
PR Newswire (Jan 22, 2013)
-
at MarketWatch.com (Jan 9, 2013)
-
at MarketWatch.com (Jan 9, 2013)
-
PR Newswire (Dec 20, 2012)
-
PR Newswire (Dec 10, 2012)
HSP vs. ETF Alternatives
Company Description
Hospira, Inc. ("Hospira") is a global specialty pharmaceutical and medication delivery company that develops, manufactures and markets products that help improve the safety, cost and productivity of patient care. Hospira's portfolio includes generic acute-care and oncology injectables, as well... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Friday, December 2, 2011, 11:35 AM Speculation that Hospira (HSP -2.3%) shares have become so cheap in the face of scrutiny for flaws in its manufacturing practices that the company may become a takeover target isn't helping the stock today. A potential FDA consent decree over alleged safety violations at one plant would slow production and perhaps even lead to a complete shutdown of the facility. Comment! [Healthcare, M&A, On the Move]
-
- View all 0 replies
-
The Wall Street Transcript
Hospira ($HSP) to Overcome FDA Setbacks and See Recovery- http://su.pr/2G38bT - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Justin M. Hall
Rx Investors' HSP-90 & Hedge Hog Pathways Index ==> INFI, MYRX, SNTA,CRIS ==> http://bit.ly/bxkxgm/ - View all 0 replies
-
Joe Kunkle
Hospira ($HSP) trading 1,700 calls, 6X average with offer side buying in September and November $55 calls $CALL - View all 0 replies
-
Joe Kunkle
Hospira ($HSP) with a buyer of 1,350 August $65/$55 strangles at $1.10, looking for volatility in the name that continues to print new highs - View all 0 replies
LATEST REPLIES